Cytek Biosciences, Inc.
DB:8EQ Stock Report
Cytek Biosciences Past Earnings Performance Cytek Biosciences's earnings have been declining at an average annual rate of -39.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 21.1% per year.
Key information
-39.7%
Earnings growth rate
Life Sciences Industry Growth 26.8% Revenue growth rate 21.1% Return on equity -2.6% Net Margin -5.0% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023) Nov 07
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Second quarter 2024 earnings released: US$0.079 loss per share (vs US$0.032 loss in 2Q 2023) Aug 07
Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024 May 01
Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.012 profit in 3Q 2022) Nov 10
Show all updates
Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs System Nov 08
New major risk - Share price stability Nov 08
Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023) Nov 07
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 06
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12
Second quarter 2024 earnings released: US$0.079 loss per share (vs US$0.032 loss in 2Q 2023) Aug 07 Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024 Aug 07
Cytek Biosciences, Inc. Automates Panel Design with New Intelligent Algorithm Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. Jun 08
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024 May 10
Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024 May 01
Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024 Apr 28 Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics Cytek Biosciences, Inc. announced delayed annual 10-K filing Mar 03
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Mar 01
Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry Dec 21
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 15
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 14
Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.012 profit in 3Q 2022) Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Nov 08
Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
New minor risk - Share price stability Oct 06
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services Aug 29
Second quarter 2023 earnings released: US$0.032 loss per share (vs US$0.004 loss in 2Q 2022) Aug 09
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. May 20
First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.015 loss in 1Q 2022) May 11
Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023 May 10
Full year 2022 earnings released: EPS: US$0.018 (vs US$0.001 in FY 2021) Mar 02
Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million. Feb 14
Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Cytek Biosciences, Inc. Introduces Cytek Cloud Nov 16
Third quarter 2022 earnings released: EPS: US$0.012 (vs US$0.003 in 3Q 2021) Nov 11
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022 Nov 10
Cytek Biosciences, Inc. Names Chris Williams Chief Operating Officer Nov 01
Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
Second quarter 2022 earnings released Aug 12
Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 11
Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index Jun 26
Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022 Jun 24
Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I Director Jun 07
First quarter 2022 earnings released May 13
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022 May 12
Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 28
Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Feb 24
Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 12
Revenue & Expenses Breakdown
How Cytek Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History DB:8EQ Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 201 -10 92 41 30 Jun 24 198 -18 91 42 31 Mar 24 201 -12 92 44 31 Dec 23 193 -12 92 44 30 Sep 23 183 -14 90 43 30 Jun 23 176 -6 85 41 31 Mar 23 166 -2 77 37 31 Dec 22 164 2 68 35 30 Sep 22 155 -1 63 32 30 Jun 22 148 -3 59 30 31 Mar 22 139 -2 52 27 31 Dec 21 128 0 46 24 30 Sep 21 120 1 37 22 30 Jun 21 110 2 31 19 31 Mar 21 99 4 27 16 31 Dec 20 93 3 24 14 31 Dec 19 58 -17 17 9
Quality Earnings: 8EQ is currently unprofitable.
Growing Profit Margin: 8EQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8EQ is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.
Accelerating Growth: Unable to compare 8EQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8EQ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).
Return on Equity
High ROE: 8EQ has a negative Return on Equity (-2.64%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}